American Pacific Corporation (NASDAQ:APFC) has released the fiscal year earnings for 2009 ended September 30, 2009. The company reported revenues of 47.6 million and an operating loss of 44.2 million. The company’s adjusted EBITDA was also reported to have decreased to $32.6 from $42.8 million reported during fiscal 2008.
Penny Stock Professor, a leading financial publication, is pleased to alert investors of stocks on the move. Sign Up for our Free Penny Stock Picks.
The company hosted a conference call on Tuesday, December 22 to review the financial results. Interested parties may listen to a webcast of the conference on the company’s website, http://www.apfc.com/. The webcast will remain on the site until the next earnings release.
American Pacific Corporation (AMPAC) is a manufacturer of fine and specialty chemicals within its focused markets. The Company’s fine chemicals products represent the active pharmaceutical ingredient (API) or registered intermediate in certain anti-viral, oncology and central nervous system drugs. AMPAC’s specialty chemicals and aerospace equipment products are utilized in national defense programs and provide access to, and movement in, space, via solid propellant and propulsion thrusters. The Company generally sells its products through long-term contracts, under which it is the sole-source or limited-source supplier. AMPAC’s operations comprise four reportable business segments: Fine Chemicals, Specialty Chemicals, Aerospace Equipment and Other Businesses.
Follow us on Twitter: http://www.twitter.com/pennystockspro
Sign up for the free Penny Stock Professor newsletter. To subscribe, enter your e-mail address into the frame at the bottom of this press release or visit our website.
About Us
Penny Stock Professor is a leading stock web site that allows investors and interested parties to research stocks that are on the move. We also track small cap companies that are on the brink of a financial breakout. To feature a company on our web site please contact us at the email listed below.
Please click here to read the full disclaimer.
